Skip to main
TECH

Bio-Techne (TECH) Stock Forecast & Price Target

Bio-Techne (TECH) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 0%
Hold 82%
Sell 0%
Strong Sell 0%

Bulls say

Bio-Techne is a global life science tools company, with a strong presence in the US, Europe, and Asia-Pacific, that sells equipment, consumables, and services to life science research and diagnostic customers. The company's two segments - protein sciences and diagnostics and genomics - both have strong growth potential in the growing life sciences market. With a diverse customer base, strategic acquisitions, and a focus on sustainability, Bio-Techne is well-positioned for long-term success.

Bears say

Bio-Techne is well-positioned in the growing life sciences industry with strong sales in the protein sciences and diagnostics and genomics segments, but their exposure to the slower-growing cell therapy sector may weigh on future growth potential. The recent divestiture and brand consolidation show management's efforts to improve efficiency and margins, but potential risks and uncertainties in the cell therapy market may hinder the company's overall performance. While an upside scenario suggests potential for a higher target price, ongoing dialogue and feedback on sustainability issues could also impact the company's outlook.

Bio-Techne (TECH) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 0% recommend Buy, 82% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Bio-Techne and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Bio-Techne (TECH) Forecast

Analysts have given Bio-Techne (TECH) a Hold based on their latest research and market trends.

According to 11 analysts, Bio-Techne (TECH) has a Hold consensus rating as of Sep 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $69.55, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $69.55, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Bio-Techne (TECH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.